Top-Rated StocksTop-RatedNASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $5.43 +0.28 (+5.44%) Closing price 04:00 PM EasternExtended Trading$5.38 -0.04 (-0.83%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aclaris Therapeutics Stock (NASDAQ:ACRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aclaris Therapeutics alerts:Sign Up Key Stats Today's Range$5.02▼$5.4750-Day Range$5.12▼$6.5352-Week Range$1.74▼$6.60Volume2.43 million shsAverage Volume2.59 million shsMarket Capitalization$759.22 millionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingBuy Company Overview Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research programs are centered on potentially addressing conditions in which existing treatments have limited effectiveness or tolerability. Aclaris has developed a pipeline that has included zunsemetinib, an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being studied for inflammatory diseases, and other small-molecule therapies targeting immune and inflammatory pathways. The company has also investigated topical treatments for dermatological conditions, including atopic dermatitis and other skin disorders. Founded in 2012 and headquartered in Wayne, Pennsylvania, Aclaris previously commercialized ESKATA, a topical treatment for raised seborrheic keratoses, before discontinuing the product. The company’s current activities are primarily focused on research, clinical development and advancing its pipeline through clinical testing and potential strategic partnerships.AI Generated. May Contain Errors. Read More Aclaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreACRS MarketRank™: Aclaris Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 669th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingBuy Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 3 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAclaris Therapeutics has a consensus price target of $11.33, representing about 108.7% upside from its current price of $5.43.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aclaris Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aclaris Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aclaris Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.08% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 6.38.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 5.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.74 News SentimentAclaris Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows6 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRS Stock News HeadlinesReviewing Aclaris Therapeutics (NASDAQ:ACRS) & Nuvation Bio (NYSE:NUVB)September 27 at 4:15 AM | americanbankingnews.comAnalyzing Aclaris Therapeutics (NASDAQ:ACRS) and Janux Therapeutics (NASDAQ:JANX)September 21, 2026 | americanbankingnews.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.September 28 at 1:00 AM | Monument Traders Alliance (Ad)Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)September 19, 2026 | theglobeandmail.comAclaris Therapeutics (ACRS): Multiple Catalysts Could Make 2H 2026 A Defining PeriodSeptember 10, 2026 | rttnews.comAclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comCanaccord Genuity initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendationSeptember 3, 2026 | msn.comAclaris: Q2 Earnings SnapshotAugust 6, 2026 | chron.comSee More Headlines ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $3.01 at the start of the year. Since then, ACRS stock has increased by 80.4% and is now trading at $5.43. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The biotechnology company earned $1.63 million during the quarter, compared to analyst estimates of $1.38 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 61.65% and a negative net margin of 921.50%. When did Aclaris Therapeutics IPO? Aclaris Therapeutics (ACRS) raised $75 million in an IPO on Wednesday, October 7th 2015. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' top institutional shareholders include BlackRock Inc. (7.19%), Braidwell LP (1.53%), Palo Alto Investors LP (1.15%) and Connor Clark & Lunn Investment Management Ltd. (0.87%). Insiders that own company stock include Braden Michael Leonard, Anand Mehra and Joseph Monahan. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/06/2026Today9/28/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ACRS's financial health is in the Green zone, according to TradeSmith. ACRS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACRS CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees73Year Founded2012Price Target and Rating Average Price Target for Aclaris Therapeutics$11.33 High Price Target$16.00 Low Price Target$10.00 Potential Upside/Downside+108.7%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$64.92 million Net Margins-921.50% Pretax Margin-921.50% Return on Equity-61.65% Return on Assets-42.41% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual Sales$7.83 million Price / Sales96.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book6.39Miscellaneous Outstanding Shares139,820,000Free Float133,112,000Market Cap$759.22 million OptionableOptionable Beta0.79 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ACRS) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
